1 / 22

Case study: Challenges and learning in implementing ATF perfusion process

Case study: Challenges and learning in implementing ATF perfusion process. Dr. Jarno Robin Principal Scientist CMC_Biopharm upstream development Novo Nordisk A/S, Hillerød, Denmark. Outline. introduction to Novo Nordisk

inoke
Download Presentation

Case study: Challenges and learning in implementing ATF perfusion process

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Case study:Challenges and learning in implementing ATF perfusion process Dr. Jarno Robin Principal Scientist CMC_Biopharm upstream development Novo Nordisk A/S, Hillerød, Denmark

  2. Outline introduction to Novo Nordisk case study: implementation of ATF perfusion process for improving yield prior to fase3 production background & timeline perfusion technology contraints new perfusion process (lab & production scales) process challenges & stabilisation conclusion: yield improvement and quality learnings

  3. Novo Nordisk Corporate strategy Novo Nordisk Way

  4. Novo Nordisk around the world production R&D, production Headquater, Research Units, R&D, production

  5. Diabetes: A global pandemic

  6. Part II case study: implementation of perfusion process for improving yield prior to fase3 production background & timeline perfusion technology contraints new perfusion process (lab & production scales) process challenges & stabilisation

  7. Background & timeline very stable & robust process (cell growth & product quality) BUT very poor productivity Issues regarding production capacity 2008 • Feb : 3-days-Draw & fill (D&F) process approved for phase3 production. Prod. Conc.

  8. Background & timeline Normalised yield improvment (%) 2008 • Feb.: 3-days-Draw & fill (D&F) process approved for phase3 production. • Oct.: process challenge meeting: approval for attempting to change the production process from D&F to a perfusion process based on expectations to increase yield significantly (shaked flasks simulation).

  9. Background & timeline 2008 • Feb.: 3-days-Draw & fill (D&F) process approved for phase3 production. • Oct.: process challenge meeting: approval for attempting to change the production process from D&F to a perfusion process based on expectations to increase significantly yield. • Nov-Dec.: Finalising the ATF purchase for lab- & production- scales. • Jan-Jun.: Implementation of ATF-2 in lab scale and ATF-10 in production scale. • Apr-Jul: TDR meetings: • production medium chosen for phase3 production (3 upstream depts. involved). • perfusion process using the ATF chosen for phase3 production (3 upstream + 1 downstream depts. involved, coordination meeting). • Jul-Aug.: Master & production formulas in place for fase3 production planed from Oct. 2009 (2 upstream depts. involved). • Q2/Q3: further process optimisation, MF/PF updated (2 upstream depts. involved). • Q4-2011/Q2-2012: issue regarding impact of complex raw-material quality on process performance (2 upstream depts. involved). • Q2/Q3: Process Justification & transfer to production support department. 2009 2011 2012

  10. Why ATF ? : Perfusion devices available Spin filter Applisens BioSep • good in lab (intern filter)  up-scaling: extern at large scale (temp., pH, O2 stress, pump & shear stress) • block at high cell conc. • cells in harvest good in lab • up-scaling, pump • 5-10% cells in harvest ATF (Alternating Tangencial Filtration) Tangential Flow Filtration (TFF) • simple & upscalable (to 5m3) • no temp., pH, O2 stress • no pump & low shear stress • cell free harvest • reasonable cost possible product binding • good in lab • cell free harvest possible product binding • pump, up-scaling

  11. ATF perfusion process at Novo Nordisk(Alternative Tangiencial Filtration) Bleed Medium Harvest Harvest Patent no.: WO2012045769

  12. Pictures of ATF (“Darth Vader” sword)

  13. New ATF-process: constraints • Harvest stability of at least 2 days due to downstream process at large scale. • Short timeline for a complete process change (Q1/Q2-2009,~6 months) • Get a scalable perfusion process to the production facility using the ATF technology. • Get similar product quality as the material produced for tox and fase1 clinical trial using the D&F process. • Improve significantly the expression level (production capacity)

  14. New process scalability from lab to production scale (2009)

  15. Challenges: Complex raw-material quality impact on process performance at large scale

  16. Challenges: Complex raw-material quality impact on process performance. Confirmation at lab scale • Soy hydrolysate has been analysed: • tracer element, • free amino acids • NIR

  17. NIR analyses on HySoy batches Work done by Erik Skibsted (ERSK)

  18. Process stabilisation: focus on Zn concentration w/o. Zn spiking w/ Zn spiking

  19. Conclusion: Yield improvment and quality

  20. Conclusion: Learnings targets achieved: new process development & implementation within short timeline (6 months) scalable perfusion process significant increase in yield (up to 600%) identical product quality between D&F and perfusion process process stabilisation after unexpected significant impact of complexe raw-material on process performance increased knowledge: solving challenges increased collaboration across lab & production scales complex raw-material characterisation know-how for next generation process and/or products for early implementation in the project plan: Focus on correlation between cell line/medium/process

  21. Aknowledgements: Dept.’s bioreactor team for dedicated technical work Production & Research Unit, up- & down-stream for good collaboration Vendors for support

  22. Thank you ! for your attention

More Related